Ceftobiprole: An Extended-Spectrum Anti–Methicillin-Resistant Staphylococcus aureus Cephalosporin

Shawn D Anderson, PharmD; John G Gums, PharmD, FCCP


The Annals of Pharmacotherapy. 2008;42(6):806-816. 

In This Article


  • Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006;5:2. DOI 10.1186/1476-0711-5-2

  • Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-74.

  • Adis R&D profile. Ceftobiprole medocaril. Drugs R D 2006;7:305-11.

  • Jones ME. In-vitro profile of a new β-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect2007;13:17-24. DOI 10.1111/j.1469-0691.2007.01722.x

  • Livermore DM. Can β-lactams be re-engineered to beat MRSA? Clin Microbiol Infect2006;12:11-6. DOI 10.1111/j.1469-0691.2006.01403.x

  • de Lencastre H, de Jonge BL, Matthews PR, Tomasz A. Molecular aspects of methicillin resistance in Staphylococcus aureus. J Antimicrob Chemother 1994;33:7-24.

  • Lim D, Strynadka NC. Structural basis for the beta-lactam resistance of PBP2a from methicillin-resistant Staphylococcal aureus. Nat Struct Biol 2002;9:870-6. DOI 10.1038/nsb858

  • Chambers HF. Solving staphylococcal resistance to beta-lactams. Trends Microbiol 2003;11:145-8. DOI 10.1016/S0966-842X(03)00046-5

  • Davies TA, Page mgP, Shang W, Andrew T, Kania M, Bush K. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother2007;51:2621-4. DOI 10.1128/AAC.00029-07

  • Georgopapadakou NH. Penicillin-binding proteins and bacterial resistance to β-lactams. Antimicrob Agents Chemother1993;37:2045-53.

  • Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P, Page mg, Then RL. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother2001;45:825-36. DOI 10.1128/AAC.45.3.825-836.2001

  • Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrobial Chemother2002;50:915-32. DOI 10.1093/jac/dkf249

  • Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infections. Diag Microbiol Infect Dis2007;58:363-5. DOI 10.1016/j.diagmicrobio.2007.02.010

  • von Eiff C, Friedrich AW, Becker K, Peters G. Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes. Antimicrob Agents Chemother2005;49:4372-4. DOI 10.1128/AAC.49. 10.4372-4374.2005

  • Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother2005;49:4210-9. DOI 10.1128/AAC.49.10.4210-4219.2005

  • Denis O, Deplano A, Nonhoff C, et al. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob Agents Chemother2006;50:2680-5. DOI 10.1128/AAC.00272-06

  • Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother2005;49:884-8. DOI 10.1128/AAC.49.3.884-888.2005

  • Deshpande LM, Jones RN. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin Microbiol Infect 2003;9:1120-4. DOI 10.1046/j.1469-0691.2003.00765.x

  • Yun HC, Ellis MW, Jorgensen JH. Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees. Diag Microbiol Infect Dis 2007;59:463-6. Epub 29 Oct 2007. DOI 10.1016/j.diagmicrobio.2007.06.023

  • Lin G, Appelbaum PC. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis. Diag Microbiol Infect Dis2008;60:233-5. Epub 7 Nov 2007. DOI 10.1016/j.diagmicrobio.2007.09.012

  • Kosowska K, Hoellman DB, Lin G, et al. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005;49:1932-42. DOI 10.1128/AAC.49.5.1932-1942.2005

  • Davies TA, Shang W, Bush K. Activities of ceftobiprole and other β-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob Agents Chemother 2006;50:2530-2. DOI 10.1128/AAC.00238-06

  • Arias CA, Singh KV, Panesso D, Murray BE. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J Antimicrob Chemother2007;60:594-8. Epub 2 Jul 2007. DOI 10.1093/jac/dkm237

  • Arias CA, Singh KV, Panesso D, Murray BE. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including β-lactamase–producing and vancomycin-resistant isolates. Antimicrob Agents Chemother2007;51:2043-7. Epub 16 Apr 2007. DOI 10.1128/AAC.00131-07

  • Queenan AM, Shang W, Kania M, Page mgP, Bush K. Interactions of ceftobiprole with β-lactamases from molecular classes A to D. Antimicrob Agents Chemother2007;51:3089-95. DOI 10.1128/AAC.00218-07

  • Issa NC, Rouse MS, Piper KE, Wilson WR, Steckelberg JM, Patel R. In vitro activity of BAL 9141 against clinical isolates of gram-negative bacteria. Diag Microbiol Infect Dis2004;48:73-5. DOI 10.1016/j.diagmicrobio.2003.09.006

  • Zbinden R, Punter V, von Graevenitz A. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters. Antimicrob Agents Chemother2002;46:871-4. DOI 10.1128/AAC.46.3.872-875.2002

  • Bogdanovich T, Clark C, Ednie L, et al. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother2006;50:2050-7. DOI 10.1128/AAC.00044-06

  • Goldstein EJC, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother 2006;50:3959-62. DOI 10.1128/AAC.00722-06

  • Wootton M, Bowker KE, Holt HA, MacGowan AP. BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials. J Antimicrob Chemother 2002;49:535-9.

  • Ednie L, Shapiro S, Appelbaum PC. Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin. Diag Microbiol Infect Dis 2007;58:133-6. Epub 19 Jan 2007. DOI 10.1016/j.diagmicrobio.2006.10.015

  • Deshpande L, Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against gram-positive and gram-negative isolates. Diag Microbiol Infect Dis 2004;50:73-5. DOI 10.1016/j.diagmicrobio.2004.04.011

  • Schmitt-Hoffmann A, Roos B, Schleimer M, et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother2004;48:2570-5. DOI 10.1128/AAC.48.7.2570-2575.2004

  • Schmitt-Hoffmann A, Nyman L, Roos B, et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother2004;48:2576-80. DOI 10.1128/AAC.48.7.2576-2580.2004

  • Murthy B, Schmitt-Hoffman A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet 2008;47:21-33.

  • Pankuch GA, Appelbaum PC. Postantibiotic effect of ceftobiprole against 12 gram-positive organisms. Antimicrob Agents Chemother2006;50:3956-8. DOI 10.1128/AAC.00724-06

  • Schmitt-Hoffmann A, Murthy B, Strauss RS, Pypstra R. Pharmacokinetics of multiple infusions of ceftobiprole (1000 mg every 8 hours) in healthy volunteers (poster A-1943). Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27–30, 2006.

  • Murthy B, Skee D, Wexler D, et al. Pharmacokinetics of ceftobiprole following single and multiple intravenous infusions administered to healthy subjects (poster P779). Presented at: 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, March 31–April 3, 2007.

  • Lodise TP, Pypstra R, Kahn JB, et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother2007;51:2378-87. DOI 10.1128/AAC.01181-06

  • Mouton JW, Schmitt-Hoffmann A, Shapiro S, Nashed N, Punt NC. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother2004;48:1713-8. DOI 10.1128/AAC.48.5.1713-1718.2004

  • ClinicalTrials.gov. 2007 Nov 29. Bethesda, MD: National Library of Medicine (US). https://clinicaltrials.gov/ (accessed 2007 Dec 6).

  • Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother2008;52:37-44. Epub 22 Oct 2007. DOI 10.1128/AAC.00551-07

  • Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin structure infections. Clin Infect Dis2008;46:647-55. DOI 10.1086/526527

  • Banerjee R, Chambers HF. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant S. aureus (MRSA) (poster C1-844). Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17–20, 2007.

  • Bogdanovich T, Applebaum PC. Staphylococcal single-step resistance selection studies with ceftobiprole and comparators (poster F-1163). Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16–19,2005.

  • Bogdanovich T, Bozdogan B, Applebaum PC. Resistance selection studies on staphylococci with ceftobiprole (BAL9141) (poster E-2018). Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30–November 2,2004.

  • Heller S, Marrer E, Page mgP, et al. Development of endogenous resistance by staphylococci to BAL9141 and comparators (poster P675). Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1–4,2004.

  • Queenan AM, Bush K. Ceftobiprole: effect on AmpC β-lactamase induction and resistance frequency in gram-negative bacteria (poster C1-55). Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16–19,2005


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.